Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
← catalyst calendarNCT07686081 · readout ≤ 984 d
Sponsored by Vanda Pharmaceuticals (industry) · VNDA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
150estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Apr 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis (UC)
Interventions
- Drug: Ponesimod — also filed as VSP-128
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFClinical Remission at Week 16
measured Week 16
Permalink · VNDA's whole pipeline · Catalyst calendar · Every registered study · What changed